The New Brunswick, N.J., pharmaceutical giant on Thursday said the application covers TAR-200 for the treatment of patients with Bacillus Calmette-Guerin-unresponsive high-risk non-muscle invasive ...

Discover a study that reveals a targetable CA125+ cell state in rare bladder cancer subtypes using single-cell RNA sequencing.

Johnson & Johnson (NYSE:JNJ) announced on Thursday that the U.S. FDA granted priority review for its new drug application aimed at getting marketing approval for TAR-200, a drug-releasing system for ...

Based on durable response data, TAR-200 has been given priority review for the treatment of patients with high-risk ...